This is a preview of subscription content, log in via an institution to check access.
Reference
Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017. Available from: URL: http://doi.org/10.1111/apt.14430
Rights and permissions
About this article
Cite this article
Biologics major cost driver in IBD management in the US. PharmacoEcon Outcomes News 792, 7 (2017). https://doi.org/10.1007/s40274-017-4530-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4530-6